Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Eisai Korea Inc.

Clinical trials sponsored by Eisai Korea Inc., explained in plain language.

Now part of Eisai Co., Ltd. 4523 TOKYO

The Korean subsidiary of Eisai, a Japanese pharmaceutical company.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 2 Not yet finished but already full! 1 Completed 1

New pill aims to calm ulcerative colitis flare-ups in korean patients

Disease control Ongoing

This study tests a daily medication called filgotinib (200 mg) in about 94 Korean adults with moderate-to-severe ulcerative colitis. The main goal is to see if it can bring the disease into remission (no active symptoms) by week 10 or 22. Participants take the pill once daily and…

Phase: PHASE4 • Sponsor: Eisai Korea Inc. • Aim: Disease control

Last updated Jul 04, 2026 00:00 UTC